Compare Amplify Transformational Data Sharing ETF (BLOK) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Transformational Data Sharing ETF vs Bristol-Myers Squibb Co — how do they compare? Amplify Transformational Data Sharing ETF trades at $60.34, while Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Amplify Transformational Data Sharing ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | BMY | |
|---|---|---|
52-Week High | $74.10 | $65.89 |
52-Week Low | $47.36 | $42.60 |
Market Cap | — | $129.94B |
Sector | — | Health |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with a bearish technical signal from moving averages but neutral oscillators. Support lies at $59 and resistance at $61. The ETF's financial ratios are not disclosed, and a small dividend of $0.08 is scheduled for June 2026. Recent news highlights institutional trimming and focus on AI infrastructure holdings.
Outlook remains cautious due to bearish technicals and lack of fundamental data. Risks include sector volatility and institutional selling. Opportunities may arise from AI-driven growth in portfolio companies, but investors should await clearer financial metrics for valuation.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
